Bristol-Myers' Yervoy extends lives by three years for one-fifth of melanoma patients
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb’s Yervoy helped more than a fifth of patients with advanced melanoma live at least three years longer after treatment, according to newly disclosed research of the drug.